Assay Development for Quantification of Low-Abundant Proteins Using Single Molecule Counting
What Does it Cover?
Huntington Disease is caused by the expression of a mutated form of the Huntingtin protein (mHTT) containing a polyglutamine (polyQ) repeat, with the length of the repeat correlating to increased severity of the disease. Since concentrations of total and mHTT in premanifest and controls groups are extremely low, it is imperative that detection assays are capable of reaching femtomolar levels of sensitivity. By employing SMC® technology, we can provide the HD community with tools to enable a better understanding of the disease and to assist in the development of new therapeutics.
During this webinar we will review data from the development and validation of the high sensitivity SMC® immunoassays for the quantification of mHTT and total HTT.
What Will You Learn?
For Research Use Only. Not For Use In Diagnostic Procedures.
Former Head of Custom Assays & Sample Testing Group
Sarah Hamren was the former head of the SMC® Custom Assay and Sample Testing group until 2021. She has over 30 years of experience in biopharma research and development and her past experience includes work at Chiron Corporation, Bayer Corporation’s Biotechnology division, Tethys Bioscience, and Singulex® Inc. before joining us. She is co-author on 15 peer-reviewed publications and holds 2 U.S. patents. Sarah’s experience effectively partnering with a broad array of clients has culminated in hundreds of successful biomarker assay development projects.
Research and disease areas
Session 1:presented July 7, 2020
To continue reading please sign in or create an account.Don't Have An Account?